Driving Impairment Cases Involving Etizolam and Flubromazolam

Area of Science:

• Forensic Toxicology
• Pharmacology
• Drug Enforcement

Background:

• Designer benzodiazepines, such as etizolam and flubromazolam, are emerging as substances of concern.
• Impaired driving cases present a challenge for toxicological analysis due to novel psychoactive substances.
• Routine laboratory testing may fail to detect low concentrations of these designer drugs.

Purpose of the Study:

• To report on the detection of etizolam and flubromazolam in drivers suspected of impaired driving.
• To highlight the prevalence and concentrations of these designer benzodiazepines in forensic cases.
• To emphasize the need for updated analytical methods for novel psychoactive substances.

Main Methods:

• Analysis of blood samples from 12 drivers stopped for impaired driving.
• Detection of etizolam and flubromazolam using validated analytical methods.
• Identification of co-occurring drugs, including methamphetamine, amphetamine, and tetrahydrocannabinol (THC).

Main Results:

• Etizolam detected in 3 cases (40–330 ng/mL), with co-detection of other drugs in 2 cases.
• Flubromazolam detected in 9 cases (7.0–31 ng/mL), most commonly with THC.
• Low concentrations of designer benzodiazepines were observed, posing a risk of false negatives with standard testing.

Conclusions:

• The increasing detection of designer benzodiazepines in impaired driving cases poses a significant public safety threat.
• Validated analytical methods must incorporate novel psychoactive substances like etizolam and flubromazolam.
• Forensic laboratories and investigating agencies must remain vigilant in monitoring emerging designer benzodiazepines.